Biohaven Price to Book Ratio 2016-2022 | BHVN

Historical price to book ratio values for Biohaven (BHVN) over the last 10 years. The current price to book ratio for Biohaven as of February 03, 2023 is 13.70.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biohaven Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-02-03 18.19 12.37
2022-09-30 151.17 $1.47 102.82
2022-06-30 145.71 $-11.33 -12.86
2022-03-31 118.57 $-6.61 -17.93
2021-12-31 137.81 $0.52 265.89
2021-09-30 138.91 $-9.03 -15.38
2021-06-30 97.08 $-7.00 -13.87
2021-03-31 68.35 $-4.28 -15.99
2020-12-31 85.71 $-6.49 -13.21
2020-09-30 65.01 $-3.58 -18.15
2020-06-30 73.11 $-0.60 -122.71
2020-03-31 34.03 $2.09 16.29
2019-12-31 54.44 0.00
2019-09-30 41.72 $2.28 18.31
2019-06-30 43.79 $3.63 12.08
2018-12-31 36.98 $3.41 10.83
2018-09-30 37.55 $1.63 22.97
2018-06-30 39.52 $2.96 13.33
2018-03-31 25.76 $2.79 9.22
2017-12-31 26.98 $3.66 7.37
2017-09-30 37.38 $4.35 8.60
2017-06-30 25.00 $5.37 4.66
2019-03-31 51.47 $2.19 23.49
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.307B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00